NFκB activation is sufficient and necessary to induce endothelial to mesenchymal transition in aortic valve endothelial cells, driving susceptibility to calcification and suggesting a potential early intervention target for calcific aortic valve disease.
Answers are grounded in this paper and cite their sources.
NFκB overexpression promotes osteogenic transition in valve endothelial cells; leaves open its role as a therapeutic target in calcific aortic valve disease.
Treatment of calcific aortic valve disease (CAVD) remains difficult due to limited understanding of the initial pathological activators. The early inflammation stage is known to stimulate an endothelial to mesenchymal transition (EndMT) of valve endothelial cells (VEC), but the role of the transformed cells in later disease is unknown. Characterization of EndMT VEC revealed high expression of NFκB, α-SMA, Snai1, MMP-9, and extracellular matrix remodeling capabilities. Transfection of VEC with NFκB over-expression and inhibition plasmids showed that NFκB is sufficient and necessary to induce EndMT. Further, when cultured in an osteogenic environment, VEC+NFκB had increased α-SMA (50.4+/− 3.1 fold), osteocalcin (16.1+/−1.8 fold) runx-2 (14.7+/−.8 fold), and calcium deposition compared to controls. In diseased human valves, cells with activated NFkB localized near calcific nodules and co-expressed CD31 and α-SMA, suggesting EndMT origin. Together, these results suggest that transformed VEC are key players in aortic valve calcification and NFκB-inhibition is an attractive valve specific intervention strategy in the early stages of CAVD.
No takes yet. Share an insight, caveat, or question.
Farrar et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: